-
Cotation en bourse
Connecting Europe's Fixed Income MarketsOne connected fixed income ecosystemLire la suiteSeamless listing, trading, clearing and settlement for fixed income
-
Trading
Where European Government Bonds meet the futureFixed Income derivativesLire la suite
Trade Mini Bond Futures on main European Government Bonds
-
Clearing
Connecting Europe's Fixed Income MarketsOne connected fixed income ecosystemLire la suite
Seamless listing, trading, clearing and settlement for fixed income
-
CSD
European CSD modelBuilding the CSD of Choice in EuropeLire la suiteEuronext Securities is shaping the future of European capital markets by enhancing integration, connectivity, and innovation.
-
Technology
Euronext Technology SolutionsHigh-Frequency Trading Solution (HFTS)Lire la suiteThe new generation of high-frequency risk trading platforms, offering the highest performance with ultra-low latency and minimal jitter, all at a low total cost of ownership.
-
Données de marché
-
Indices
Access the white paperNext generation of indicesLire la suiteThis white paper marks the second edition of Euronext’s Index Outlook series, a recurring publication designed to give investors deeper insight into our index innovation agenda and the structural forces shaping global markets.
-
About Euronext
Euronext strategic planInnovate for Growth 2027Lire la suiteShaping capital markets for future generations
ASIT biotech
11/05/2016
ASIT biotech fait ses premiers pas en Bourse
Euronext Bruxelles et Paris ont accueilli aujourd’hui ASIT biotech, une société belge spécialisée dans le traitement des allergies. Thierry Legon, CEO d’ASIT biotech, a sonné la cloche d’ouverture des marchés à Bruxelles pour saluer la première cotation de la société qui a levé 23,5 € millions lors de cette IPO. ASIT biotech rejoint de la sorte une communauté de 77 sociétés spécialisées dans les sciences de la vie cotées sur les marchés Euronext.